ID   CADO-ES1
AC   CVCL_1103
SY   CADO-ES-1; Cado-ES-1; CADO ES1; CADOES1; CADO-ES; Cado-ES; ESCADO1; Center for Adult Diseases Osaka-Ewing Sarcoma 1
DR   CLO; CLO_0002173
DR   EFO; EFO_0002818
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-6067
DR   ArrayExpress; E-MTAB-6111
DR   BioSample; SAMN03473333
DR   BioSample; SAMN10988559
DR   Cell_Model_Passport; SIDM00961
DR   CLS; 300127/p767_CADO-ES1
DR   Cosmic; 753539
DR   Cosmic; 1718434
DR   Cosmic; 2294581
DR   Cosmic-CLP; 753539
DR   DepMap; ACH-000210
DR   DSMZ; ACC-255
DR   EGA; EGAS00001000978
DR   GDSC; 753539
DR   GEO; GSM510004
DR   GEO; GSM886901
DR   GEO; GSM887966
DR   GEO; GSM1669643
DR   IARC_TP53; 21207
DR   LiGeA; CCLE_114
DR   PharmacoDB; CADOES1_162_2019
DR   Progenetix; CVCL_1103
DR   Wikidata; Q54808333
RX   PubMed=1756482;
RX   PubMed=11668190;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=22142829;
RX   PubMed=22460905;
RX   PubMed=23637631;
RX   PubMed=25984343;
RX   PubMed=26428435;
RX   PubMed=27397505;
RX   PubMed=29464090;
RX   PubMed=30563222;
RX   PubMed=30879952;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=33460449;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 48 hours (PubMed=25984343); ~40 hours (CLS); ~35 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
CC   Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=26428435; PubMed=33460449).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.63%; Native American=0.72%; East Asian, North=75.38%; East Asian, South=21.78%; South Asian=0%; European, North=0%; European, South=0.48% (PubMed=30894373).
CC   Caution: Was incorrectly indicated to have an EWSR1-FLI1 (EWS-FLI1) gene fusion in PubMed=23637631.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=19787792; PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,13
ST   D16S539: 9,11
ST   D18S51: 15,20
ST   D19S433: 13.2,15.2
ST   D21S11: 31,32.2
ST   D2S1338: 22,25
ST   D3S1358: 16,18
ST   D5S818: 11,12
ST   D7S820: 11,13
ST   D8S1179: 12,15
ST   FGA: 21,22
ST   Penta D: 13
ST   Penta E: 12,19
ST   SE33: 19,28.2
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 28
//
RX   PubMed=1756482; DOI=10.1016/0165-4608(91)90185-W;
RA   Kodama K., Doi O., Higashiyama M., Mori Y., Horai T., Tateishi R.,
RA   Aoki Y., Misawa S.;
RT   "Establishment and characterization of a new Ewing's sarcoma cell
RT   line.";
RL   Cancer Genet. Cytogenet. 57:19-30(1991).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23637631; DOI=10.1371/journal.pgen.1003464;
RA   Giacomini C.P., Sun S., Varma S., Shain A.H., Giacomini M.M.,
RA   Balagtas J.M.S., Sweeney R.T., Lai E., Del Vecchio C.A., Forster A.D.,
RA   Clarke N., Montgomery K.D., Zhu S., Wong A.J., van de Rijn M.,
RA   West R.B., Pollack J.R.;
RT   "Breakpoint analysis of transcriptional and genomic profiles uncovers
RT   novel gene fusions spanning multiple human cancer types.";
RL   PLoS Genet. 9:E1003464-E1003464(2013).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29464090; DOI=10.18632/oncotarget.23815;
RA   Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W.,
RA   Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M.,
RA   Meltzer J., Farwick N., Greune L., Rossig C.;
RT   "T cell infiltration into Ewing sarcomas is associated with local
RT   expression of immune-inhibitory HLA-G.";
RL   Oncotarget 9:6536-6549(2018).
//
RX   PubMed=30563222; DOI=10.3390/ijms19123908;
RA   Hotfilder M., Mallela N., Seggewiss J., Dirksen U., Korsching E.;
RT   "Defining a characteristic gene expression set responsible for cancer
RT   stem cell-like features in a sub-population of Ewing sarcoma cells
RT   CADO-ES1.";
RL   Int. J. Mol. Sci. 19:3908.1-3908.23(2018).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=33460449; DOI=10.1002/ijc.33474;
RA   Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J.,
RA   Nagel S., Steenpass L., Becker J.;
RT   "Cross-contamination meets misclassification: awakening of CHP-100
RT   from sleeping beauty sleep - a reviewed model for Ewing's sarcoma.";
RL   Int. J. Cancer 148:2608-2613(2021).
//